Search

Roivant Sciences Ltd

Cerrado

SectorSanidad

36.29 2.63

Resumen

Variación precio

24h

Actual

Mínimo

35.05

Máximo

36.47

Métricas clave

By Trading Economics

Ingresos

669M

356M

Ventas

521K

2.5M

Margen de beneficios

14,116.825

Empleados

721

EBITDA

744M

455M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+3.76% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

5.6B

26B

Apertura anterior

33.66

Cierre anterior

36.29

Noticias sobre sentimiento de mercado

By Acuity

24%

76%

68 / 342 Clasificación en Healthcare

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 jul 2026, 23:41 UTC

Correlated Moves
Social Media
News

Micron Technology shares are lower in after-market trading, reflecting broader market pressures and concerns over a potential memory oversupply by 2028.

6 jul 2026, 23:31 UTC

Correlated Moves
News
Social Media

Microsoft Corp announced layoffs of about 4,800 employees, primarily in its Xbox division. Shares are lower in after-market trading following the news.

6 jul 2026, 23:26 UTC

Correlated Moves
News

Analog Devices Inc. is advancing in after-market trading, driven by a rebound in the semiconductor sector and bullish updates from UBS and Goldman Sachs.

6 jul 2026, 23:02 UTC

Social Media
News

Vertex Pharmaceuticals shares declined in after-market hours following its $10 billion acquisition of Crinetics Pharmaceuticals at $85 per share, expected to close in 2026.

6 jul 2026, 20:51 UTC

News
Correlated Moves

Invesco CurrencyShares Euro Trust is gaining in after-market trading, influenced by comments from Federal Reserve Governor Christopher Waller on monetary policy complexities.

6 jul 2026, 20:07 UTC

News

Verisign shares are higher amid reported $1.1 billion in free cash flow, though concerns linger over AI advancements and upcoming contract renewals.

6 jul 2026, 20:07 UTC

News
Social Media

Netflix Inc faces engagement issues, prompting bearish investor sentiment. The stock is trading lower amid concerns ahead of its upcoming earnings report.

6 jul 2026, 20:07 UTC

Social Media
News
Macro Event

PayPal Holdings Inc. shares are lower as recent ISM Services data showed a slowdown in growth, with the PMI declining from the previous month.

6 jul 2026, 20:07 UTC

Correlated Moves
News

Ethereum is advancing, supported by Tom Lee's BitMine purchasing $74 million in the asset, raising their total holdings to 5,742,237 ETH.

6 jul 2026, 20:07 UTC

Correlated Moves
News

Bitcoin trades higher, recovering from earlier lows, amid stable cryptocurrency market conditions and concerns over inflation and interest rates. Current price is $61,750.

6 jul 2026, 20:07 UTC

News
Correlated Moves

Bitcoin's value has risen since Sunday, reaching around $61,750. This increase occurs amid broader cryptocurrency market weakness and concerns over inflation and interest rates.

6 jul 2026, 20:07 UTC

Social Media
News

Adobe Inc. shares are lower amid scrutiny of first-quarter results and competitive pressures from Canva and Figma, with support noted at $215.

6 jul 2026, 20:07 UTC

News
Social Media

Apple Inc. shares are higher following an extended partnership with Broadcom for custom chips through 2031 and the reintroduction of card payments in India.

6 jul 2026, 20:06 UTC

Event
News

Cisco Systems Inc shares are higher today as the company went ex-dividend, distributing $0.42 per share, amid positive analyst upgrades.

6 jul 2026, 20:06 UTC

News

Ulta Beauty Inc. shares are lower amid declines in the Other Specialty Retail sub-sector and broader market weakness, trading near the bottom of its one-month range.

6 jul 2026, 20:06 UTC

Social Media
News

Scotiabank upgraded Check Point Software to Sector Outperform, setting a price target of $185, following its 2025 ESG Report release. Shares are higher since Thursday's close.

6 jul 2026, 20:06 UTC

News

Cintas Corp shares are lower today, continuing a broader market decline since Thursday. The stock peaked early but has trended downward since.

6 jul 2026, 20:06 UTC

News

Cadence Design Systems reported first-quarter revenue of $1.474 billion, an 18.7% year-over-year increase, and a record backlog of $8 billion. Shares are trading higher.

6 jul 2026, 20:06 UTC

News

Amgen shares are lower as Cantor Fitzgerald maintains a Neutral rating with a $350 price target, reflecting cautious investor sentiment amid recent volatility.

6 jul 2026, 20:04 UTC

News
Social Media

Tesla shares are higher today, fueled by strong second-quarter delivery figures and the positive reception of its robotaxi service in Miami.

6 jul 2026, 20:02 UTC

News

Align Technology shares are higher today following a rating upgrade to "strong-buy" from Wall Street Zen, despite a downgrade from Weiss Ratings.

6 jul 2026, 20:02 UTC

News

Mondelez International shares are lower amid weakness in the Packaged Foods & Meats sector. The stock remains near the lower end of its one-month trading range.

6 jul 2026, 20:02 UTC

News
Social Media
Correlated Moves

Qualcomm's stock rises as Nvidia's CEO endorses its AI tech and Bernstein raises its price target. A partnership with Meta also boosts investor interest.

6 jul 2026, 20:02 UTC

News
Social Media

Gilead Sciences is trading lower amid a Biotechnology sector decline, despite HSBC's upgrade to Buy and a raised price target of $155.

6 jul 2026, 20:02 UTC

Macro Event
News

J B Hunt shares decline after Morgan Stanley downgraded the stock to Underweight, raising the price target to $200 from $190 amid sector concerns.

6 jul 2026, 19:57 UTC

News
Social Media

Berkshire Hathaway has tripled its stake in Alphabet, boosting investor sentiment. Alphabet's inclusion in the Dow Jones further underscores its growth potential.

6 jul 2026, 19:56 UTC

News

Natural gas is trading higher today, maintaining an upward trajectory above its 20-day moving average. ProShares Ultra Bloomberg Natural Gas has gained since Thursday's close.

6 jul 2026, 19:53 UTC

News

Charter Communications Inc is declining amid low demand for services and stagnant returns on capital. Analysts rate the stock as "Reduce," reflecting a cautious outlook.

6 jul 2026, 19:52 UTC

Social Media
News

Evercore ISI raised its price target on Illumina to $200, maintaining an Outperform rating. Shares are trading higher amid positive sentiment and social media discussions.

6 jul 2026, 19:51 UTC

Social Media
News

Bank of America upgraded T-Mobile US Inc to Buy, maintaining a $220 price target, citing overstated competition concerns and the company's urban market dominance.

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

3.76% repunte

Estimación a 12 Meses

Media 36.72 USD  3.76%

Máximo 42 USD

Mínimo 29.29 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

7

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

68 / 342 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat